Understanding how the DEA classifies cannabis compounds is essential for patients and providers navigating the increasingly complex legal landscape between hemp, CBD, and controlled substances. The DEA has published an updated collection of cannabis-related regulatory and scheduling documents, providing a consolidated federal reference for the current legal classification and enforcement framework surrounding marijuana and hemp-derived cannabinoids. These documents detail the Controlled Substances Act scheduling criteria, enforcement guidance, and regulatory interpretations that shape how cannabis products are classified at the federal level.
Munchies Phenomenon: WSU Study Looks into Benefits of Cannabis Use and Appetite
Scientists have now proven that cannabis-triggered appetite is a real brain response that could be harnessed to help patients with HIV/AIDS and cancer who struggle to eat enough to maintain their health. A Washington State University and University of Calgary study published in PNAS confirmed that cannabis-induced appetite stimulation is a real, brain-mediated phenomenon that occurs universally regardless of sex, age, BMI, or recent food intake. In a randomized clinical trial of 82 volunteers, participants who vaped cannabis ate significantly more food within 30 minutes than the placebo group.
Full-Spectrum Cannabis Extract Shows Significant Pain Reduction in Chronic Neuropathic Pain
If you live with chronic nerve pain, this study provides clinical evidence that full-spectrum cannabis extracts can deliver meaningful relief with fewer side effects than many conventional pain medications. A clinical study found that a full-spectrum cannabis extract containing a balanced ratio of THC and CBD produced statistically significant reductions in chronic neuropathic pain compared to placebo. Patients reported meaningful improvements in pain intensity, sleep quality, and overall quality of life with minimal adverse effects.
Study: Teen Cannabis Use Linked to Double Psychosis Risk
This is one of the largest studies ever conducted on teen cannabis use and psychiatric outcomes, and it reinforces that age restrictions and youth prevention should be central to any legalization framework. A JAMA Health Forum study of 463,396 adolescents ages 13 to 17 found cannabis use was linked to a twofold increase in psychotic and bipolar disorder risk by age 26. The study represents one of the largest longitudinal investigations of this association, drawing on clinical health records rather than self-reported data.
Cannabis Use by Teenagers Doubles Their Risk of Developing Psychotic and Bipolar Disorders
With cannabis potency at historic highs, this study underscores that adolescent brains are uniquely vulnerable to THC exposure, and parents should understand the psychiatric risks before dismissing cannabis as harmless. Data from a JAMA Health Forum study of nearly half a million teenagers demonstrates that adolescent cannabis use doubles the risk of psychotic and bipolar disorder diagnoses by early adulthood. The association persisted across demographic subgroups and was temporally consistent, with cannabis use preceding psychiatric diagnoses by roughly two years on average.
Adolescent Cannabis Use Linked to Doubling Risk of Psychotic and Bipolar Disorders
Nearly half a million teens were tracked in this study, and the data shows cannabis use during adolescence meaningfully increases the chance of serious psychiatric diagnoses in early adulthood. A large longitudinal cohort study published in JAMA Health Forum tracked 463,396 adolescents and found that cannabis use between ages 13 and 17 was associated with approximately double the risk of psychotic and bipolar disorders by age 26. Elevated risks for depression and anxiety were also observed.
Kaiser Study Finds Higher Risk of Psychiatric Disorders in Teens Who Use Cannabis
If your teenager uses cannabis, this large-scale study suggests the psychiatric risks are real and significant, particularly for psychosis and bipolar disorder during a critical window of brain development. A Kaiser Permanente-led study published in JAMA Health Forum followed over 463,000 adolescents aged 13 to 17 through age 26 and found that past-year cannabis use was associated with a doubled risk of developing psychotic and bipolar disorders. Cannabis use preceded psychiatric diagnoses by an average of 1.7 to 2.3 years, suggesting a temporal relationship between adolescent exposure and later psychiatric illness.
D.C. Tightens Cannabis Ads and Virginia Moves Toward Adult-Use Sales
The DMV cannabis landscape is evolving fast: D.C.: Tightening ads — limiting youth exposure, content rules Virginia: Building retail framework — July applications, Nov sales One jurisdiction refining. One building from scratch. Both navigating the same federal uncertainty. Progress looks different everywhere. But it’s all progress. Outlaw Report covers two significant developments in the DMV cannabis landscape. Washington D.C.
Arizona Senators Approve Measures to Criminalize ‘Excessive’ Marijuana Use While Driving
D.C. is tightening cannabis advertising to protect young people while Virginia is building a regulated market from scratch—both developments show cannabis policy is maturing toward responsible frameworks. Arizona state senators approved measures to criminalize ‘excessive’ marijuana levels while driving, establishing impairment thresholds for cannabis-intoxicated driving. The legislation represents the evolving challenge of setting scientifically valid DUI standards for cannabis, as THC metabolites persist in the body long after impairment fades.
Ohio Issues Recall on Some THC Gummies
Arizona is trying to set fair limits for cannabis-impaired driving, but the science is tricky—THC stays in your system long after the effects wear off, so testing positive doesn’t necessarily mean you’re impaired. Ohio regulators have issued a recall on certain THC gummies due to quality or safety concerns in the state’s regulated cannabis market. The recall underscores the importance of robust product testing and consumer protection in legal cannabis markets.